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Sjogren's syndrome, one of the most common autoim-
mune diseases, is characterized hy cell-mediated lym-
phocytic infiltration of the exocrine glands, particularly
the salivary and lacrimal glands.' It receives little
attention in the literature, and frequently goes unrecog-
nized until progressive changes are apparent. This arti-
cle aids nurse practitioners in diagnosing the disorder
in its earliest stages and in initiating proper treatment.
Sjogren's syndrome was first identified in 1933 by aSwedish ophthalmologist named Henrik Sjögren, whoreported the association between dryness of the mouth
(xerostomia), dryness of the eyes (xerophthalmia), and chronic
deforming arthritis. It can develop as a primary disorder (clas-
sic clinical features include parotid gland enlargement, xerosto-
mia, and xerophthalmia), or it may be secondary to an
extraglandular connective tissue disease, typically rheumatoid
arthritis (RA), systemic lupus erythematosus (SLF), polymyosi-
tis, systemic sclerosis, or biliary cirrhosis.'' Primary Sjogren's is
sometimes referred to as keratoconjunctivitis sicca (KCS), the
sicca complex, or the sicca syndrome. In either its primary or
secondary form, Sjogren's syndrome may progress in severity
and lead to end-organ damage.
Incidence
Sjogren's syndrome affects 2 to 4 million persons in the United
States, predominantly middle-aged women in the peri-
menopausal or postmenopausal stage of life (it is 10 times more
common in females than in males). The mean age at diagnosis is
50 years.̂  Sjogren's syndrome occurs in persons of all races, but
it is rarely seen in children. Thirty percent of patients with
autoimmune rheumatic disease suffer from secondary Sjogren's.'
Pathophysiology
The pathophysiologic process appears to be autoimmune in
nature. Antibodies produce sensitized lymphocytes, which
selectively seek, infiltrate, and destroy exocrine glandular tis-
sue. This phenomenon is characterized clinically by depressed
production of tears and saliva.̂  Over time, the attack on the
body's immune system may lead to inflammation of internal
organs, causing irreversible damage. The specific cause of
Sjogren's remains unknown, but it is likely that genetic, envi-
ronmental, and infectious factors are involved.^ Retroviruses,
Fpstein-Barr virus (FBV), and, most recently, hepatitis C \arus
(HCV) have been implicated as causative pathogens.' Fvidence
also suggests that certain hormones, particularly estrogen, may
influence the autoimmune response in a manner simflar to that
noted in diabetes or thyroiditis."
Clinical Presentation
In clinical practice, two presentations of Sjogren's syndrome are
seen most frequently. One is the rapid development of severe
xerostomia and xerophthalmia, which is frequently accompa-
nied by episodic parotid swelling in an otherwise healthy per-
son (primary Sjogren's). Female patients are also likely to
experience vaginal dryness. The other presentation is the insid-
ious and slowly progressive development of the sicca complex
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in patients with RA or another connective
tissue disorder (secondary Sjogren's).'"
Because the s)'mptoms of decreased sali-
vary and lacrimal function are often sub-
tle, the diagnosis is often delayed until
severe symptoms are present. Other early
manifestations of secondary Sjögrens
syndrome may include fatigue, arthral-
gias, Raynaud's phenomenon (intermit-
tent bilateral ischemia of the fingers, toes,
and sometimes the ears and nose, with
severe pallor and often paresthesias and
pain, usually brought on by cold and
relieved by heat), loss of appetite, and
weight loss. It is not uncommon for 8 to
10 years to elapse between symptom
onset and the development of extraglan-
dular complications.'
Diagnosis
As an autoimmune disease, Sjögren's
syndrome can pose a challenge to pri-
mary care practitioners in terms of diag-
nosis, particularly in the early stages.
An accurate diagnosis of Sjogren's is
obtained through a comprehensive his-
tory, a focused physical examination,
and selective diagnostic testing. Table 1
lists signs and symptoms that are char-
acteristic of the syndrome. These clinical
features should be considered in tbe
review of symptoms when Sjögren's is
part of the differential diagnosis.^ Table
2 lists the San Diego diagnostic criteria
for Sjögrens syndrome.' These criteria
are stringent, requiring evidence for an
autoimmune process associated with
destruction of salivary and lacrimal
gland ttssues. At the other extreme, sev-
eral groups (including the Copenhagen
and EEC Study group) have based their
diagnostic criteria for Sjögren's syn-
drome on clinical findings of dry eyes
and mouth, with no absolute require-
ment for gland biopsy or presence of
autoantibodies.' The EEC study group
believes that the San Diego criteria iden-
tify only the tip of the iceberg—namely,
those patients with full-blown disease—
and ignore those patients with milder
forms of Sjögren's syndrome.'
Differential Diagnosis—Sjögren's
syndrome is not the only disease process
that can cause lacrimal and salivary
gland dysfunction. A comprehensive dif-
ferential diagnosis must be considered
TABLE 1 SIGNS AND SYMPTOMS OF SJÖGREN'S SYNDROME^
ORAL/SALIVARY MANIFESTATIONS
Dry moufh
Fissures and ulcers of fhe tongue,
buccal mucosa, and lips
Pefechial lesions on fhe hard palafe
Lichen planus-like appearance of
buccal mucosa
Cobblesfone appearance of fongue
Inflamed oral mucous membranes
Parofid gland hardening and/ar
enlargement
Dental caries
Adherence of food fo mucosal
surfaces
Dysphagia (especially dry foods)
Difficulty chewing
Reduced salivary flow rates



























































Extra-articular features of rheumafoid
arthrifis in secondary Sjögren's
syndrome
Myalgias
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TABLE 2 SAN DIEGO CRITERIA FOR DIAGNOSIS OF SJOGREN'S SYNDROME
The diagnosis of prirriary Sjogren's syndrome is made when two of the following
three cardinal features are present:'
1. Symptoms and objective signs of ocular dryness (Schirmer's test: <8-mm
wetting per 5 minutes, and positive rose bengai staining of cornea to
demonstrate keratoconjunctivitis sicca)
2. Symptoms and objective signs of dry mouth
-Decreased parotid flow rate using Lashley cups or other methods; and
-Abnormal findings from biopsy of minor salivary gland (based on
average of four évaluable lobules)
3. Serologie evidence of systemic autoimmunity
-Elevated rheumatoid factor >1:32O; or
-Elevated antinuclear antibody >1:320; or
-Presence of anti-SS-A(RO) or anti SS-B(LA) antibodies
The diagnosis of secondary Sjogren's syndrome is made when characteristic
signs and symptoms of Sjogren's syndrome (as described above) are present
along with clinical features sufficient to allow for a diagnosis of rheumatoid arthri-
tis, systemic lupus erythematosus, polymyositis, scleroderma, or biliary cirrhosis.
for primary care patients presenting
with dry eyes or mouth and parotid
gland enlargement. Nurse practitioners
(NPs) need to differentiate Sjogren's
from other infiltrative processes, auto-
immune diseases, and toxic insults
(Table 3). Lack of an absolute laboratory
marker of Sjogren's necessitates a diag-
nosis based on a combination of factors:
the presence of auto-antibodies, other
assessments, and a cUnical correlation.*
Diagnostic Testing—Selective diag-
nostic studies are necessary to aid in the
accurate diagnosis of Sjogren's syn-
drome. According to the San Diego cri-
teria, immunologie tests are not
diagnostic by themselves, but they are
very helpful when interpreted in con-
junction with findings from the history
and clinical exam. Once immunologie
tests are performed during the initial
evaluation, they are generally not
repeated often. Primary care providers
should use the following list of laborato-
ry studies to differentiate Sjogren's from
other immune disorders:
Minor salivary gland biopsy remains
the gold standard for definitive diagnosis
of Sjogren's syndrome. A probable diag-
nosis of the syndrome can be based on
documented decreased salivary function.'
Sjogren's antibodies are frequently
found in patients with Sjogren's syn-
drome. In 80% of patients with primary
Sjogren's, anti-SSA (formerly SS-A/Ro)
and anti-SSB (formerly SS-B/La) anti-
bodies are present. However, these anti-
bodies are not specific to Sjogren's
syndrome, as they are found in 20% to
60% of patients with SLE and in 3% to
10% of those with RA.'°
Rheumatoid factor (RF) is com-
monly found in patients with RA, but it
may also be found in patients with other
connective tissues diseases, including
Sjogren's syndrome. A positive RF in a
patient with Sjogren's syndrome does
not necessarily indicate that he or she
has RA as well. An elevated RF (>l:320)
and the presence of anti-SSA or anti-SSB
antibodies provides evidence of sys-
temic autoimmune disease.'
Antinuclear antibody (ANA) is
measured to aid in diagnosing SLE. An
elevated ANA value (>l:320) signals that
practitioners should continue their
investigation for autoimmune involve-
ment. The ANA titer may be positive in
patients with Sjogren's as well; 90% of
those with primary Sjogren's have a
speckled ANA pattern that is typical for
this disorder." However, this test alone
cannot be used to make a definitive diag-
nosis of SLE (or Sjogren's syndrome, for
that matter) without other accompany-
ing signs and symptoms.'^ Clinical fea-
tures and exam findings have a higher
degree of importance in assessing disease
activity than does an ANA titer alone.'
Erythrocyte sedimentation rate
(ESR) is helpful in identifying patients
who might have a systemic inflammato-
ry disorder or a connective tissue disor-
ders. An elevated ESR is found in
approximately 70% of patients with
Sjogren's syndrome.'
Immunoglobulins or gamma glob-
ulins are elevated in many patients with
Sjogren's syndrome, especially when
there is parenchymal involvement.
Immunoglobulin (Ig)G, IgA, and IgM
antibodies are helpful in monitoring dis-
ease activity, particularly in patients
treated with high-dose prednisone and
cyclophosphamide.
Additional Diagnostic Testing—
NPs should perform a urinalysis and
measure blood urea nitrogen and crea-
tinine to determine whether patients
with suspected or documented
Sjogren's syndrome have renal in-
volvement or inflammatory changes.
Chest radiograms may help to assess
for subtle signs of inflammation such
as pneumonitis.
Salivary function tests demonstrate
the amount of saliva production, and,
indirectly, the extent of mucosal dry-
ness. Methods of evaluating salivary sta-
tus include sialometry, sialography,
sialochemistry, and imaging (ultra-
sonography, computed tomography,
magnetic resonance imaging [MRI]).'"
Ultrasonography or MRI of the parotid
glands is useful for determining the
presence of glandular cysts, enlarge-
ment, and chronic inflammation.
Secretory sialography, an invasive proce-
dure, is not typically used in primary
care management.^
Confirmation of destructive lympho-
cytic infiltration can be obtained by
biopsy of the minor salivary glands in
the lower lip. Lesions appear as clusters
of lymphocytes that replace and destroy
the secretory acinar tissue. Presence of
this pattern is characteristic of Sjogren's
syndrome.
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^ ^ 9 DIFFERENTIAL DIAGNOSIS
PAROTID GLAND ENLARGEMENT
Bilateral
Viral infections: mumps, mononucleo-

















EBV = Epstein-Barr virus; CMV =
cytomegalovirus; HIV = human immuno-
deficiency virus; HCV = hepatitis C



























Environmental factors (eg, low
humidity, cigarette smoke expo-
sure, high wind environments)
Schirmer's test, which uses filter
paper to evaluate tear formation by the
lacrimal gland, is easy for NPs to per-
form in practice. A strip of Whatman
No. 41 filter paper is placed under the
conjunctival sac for 5 minutes, after
which the moistened portion of the
paper is measured. Wetting of less than
5 mm is a strong indicator of diminished
tear secretion (normal tear production is
>10 mm). More reliable diagnostic mea-
sures include ocular staining with rose
bengal dye and biomicroscopy (slit lamp
evaluation). Staining of either the con-
junctiva or cornea, best seen váth the
biomicroscope, indicates that small
superficial erosions are present—a sign
of primary Sjögren's syndrome.
Treatment
Once NPs make the diagnosis of
Sjögren's syndrome, they should use a
collaborative approach in terms of
managing the disease in order to
enhance patient comfort and prevent
complications. An ophthalmologist and
a dentist and/or otorhinolaryngologist
should be consulted for management
issues specific to the patient's sympto-
matology. A rheumatologist or immu-
nologist may be consulted in patients
with an exacerbation of symptoms or
for re-evaluation. Although Sjögren's is
a chronic, incurable illness, nearly all
patients can lead productive lives with
proper management.
At the same time, NPs should con-
sider the economic burden of the rec-
ommended treatment plan. Most of the
items discussed below are available over
the counter (OTC), and are not covered
by insurance. According to the Sjögren's
Syndrome Foundation, a typical patient
may need to spend $625 to $1500 per


















tensives; alpha and beta blockers;
parasympatholytic agents; antide-
pressants, especially tricyclic anti-
depressants; muscle relaxants;
antispasmodics
treatment approach for patients with
Sjögren's syndrome is conservative, and
is aimed at symptom control. Treatment
can be considered in three phases:
(1) external moisture replacement or
capture (especially important to treat the
oral cavity, eyes, nose, skin, and genital
tract); (2) stimulation of endogenous
secretions, (especially important for the
oral cavity); and (3) treatment of sys-
temic manifestations (ie, pulmonar}' dis-
ease, vasculitis, pseudolymphoma)."
Xerophthalmia. The cornerstone of
treatment for xerophthalmia is regular
use of artificial tears, which are used pri-
marily to increase patient comfort. A
variety of artificial aqueous or mucous
tear preparations, as well as an ocular
ointment, can be used to ease the dis-
comfort of ocular dryness (Table 4).^
Artificial tears contain a moisture com-
ponent and in some products, a preser-
vative. Preservative-free solutions are
1 6 • The Americon Journal for Nurse Proctitioners Moy2004 Vol. 8 No. 5















theoretically more prone to bacterial
infection, although many products are
packaged in single-dose vials to reduce
this risk. Preserved artificial tears may
cause burning or irritation, so alterna-
tive products must be considered in
these cases. Artificial tears can be used
as frequently as needed, and they are
available ÜTC. Some products (eg,
lubricating ointments) are more viscous
and have longer-lasting effects, but they
also leave a residue and are less pre-
ferred by patients than are the aqueous
products." They are generally reserved
for nocturnal use because they can cause
significant blurring of vision.
The following guidelines may be
useful in helping patients to find the
appropriate product(s) to meet their
needs: If artificial tears are not lasting
long enough, use a more viscous tear,
try a tear with a different osmolality use
a tear with a different vehicle, or consid-
er referral to an ophthalmologist for
punctal occlusion (see below). If tears
burn after instillation, choose a tear with
a different preservative or use a non-pre-
served tear. Patients who dwell in low-
humidity environments should start
using artificial tears as early in the
course of their disease as possible.^
If artificial tears do not provide ade-
quate lubrication and comfort, ophthal-
mologic surgery can be considered.
Punctal occlusion can provide tempo-
rary blockage with collagen plugs or
permanent occlusion with cattery or
laser treatment.^ The purpose of the pro-
cedure is to block the punctum, or tear
duct, which carries tears and debris
away from the surface of the eye.
Blocking these drainage ducts prevents
tears from draining away too quickly
and keeps the eyes lubricated.
Last, patients should consider envi-
ronmental factors that contribute to dry
eyes and cause irritation, such as low-
humidity environments (eg, highly air-
conditioned spaces, non-humidified
heated areas, airplanes), cigarette smoke,
and windy conditions. Increasing the use
of artificial tears before symptom onset
will help to alleviate discomfort and to
prevent potential corneal abrasion.^ Use
of humidifiers is helpful, as well as wear-
ing wrap-around sunglasses to decrease
tear evaporation when outdoors.
Xerostomia. Dry mouth is a major
contributing factor to dental caries. It is
important to teach patients with
Sjögren's syndrome the importance of
good oral hygiene and the need to avoid
excess sugars. Topical fluorides are war-
ranted to control tooth decay. Patients
can apply fluoride daily, and dental
hygienists can apply it at regular visits to
protect dental enamel. NPs should also
make sure that patients use their tooth-
brush correctly, and that they floss and
massage their gums to remove debris
between the teeth. Use of toothpastes
targeted at preventing periodontal dis-
ease (eg, Retardex, Biotene) can also be
helpful* Some patients obtain relief by
using oral sprays containing mucins and
glycoprotein (eg, Mouthkote, Salivart).
Some patients may need to make
dietary modifications such as ingesting
soft or moist foods only. Others who
retain salivary function may find that
salivary flow stimulation is helpful:
Sugarless gum, hard candy, and mints
can alleviate symptoms and increase
saliva production. Pilocarpine tablets (5
mg 4 times daily) can act as a pharmaco-
logie stimulant to increase salivary flow
for up to 2 hours after ingestion. The
most common side effects of pilocarpine
are sweating and gastrointestinal intoler-
ance, which are controllable by decreasing
the dose. Pilocarpine is contraindicated in
patients with a history of uncontrolled
asthma, peptic ulcer disease, acute iritis,
narrow angle glaucoma, or unstable car-
diovascular disease. Response to pilo-
carpine may take up to 6' weeks."
Cevimeline, an oral muscarinic agonist,
has been shovm to have a longer peak
onset of action than does pilocarpine,
and it is an effective adjunct to treat-
ment. The recommended dosage is 30
mg orally 3 times daily.
Excess water consumption can
remove mucus from the lining of the
buccal mucosa and should be avoided;
patients should be informed that fre-








for symptom control. NPs should also
educate patients about avoiding medica-
tions (prescription and over-the-
counter) that cause dry mouth.
Low-grade oral yeast infections are
common in patients vidth Sjögren's syn-
drome. Topical antifungal troches are
useful in treating this problem.* To
ensure optimal results, patients who
wear dentures should remove them
while the antifungal medication is dissolv-
ing in the mouth. Dentures must be treat-
ed to remove candidal organisms from the
surface. This can be accomplished by
soaking the dentures overnight in a solu-
tion of 1/700 dilution of benzalkonium
chloride and then cleaning them
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carefully with a toothbrush. In severe
cases, oral therapy with a systemic anti-
fungal may be necessary.̂
Dry skin. Frequent use of creams or
lotions may be helpful for patients expe-
riencing dry skin. Vaginal dryness is also
a problem for women, and can lead to
dyspareuma. Many different vaginal
lubricants, including topical estrogen,
are available to treat this problem.^
Systemic Manifestations—Whereas
many patients with Sjogren's syndrome
require only local moisturizing therapy
for xerostomia or KCS, others may need
systemic medication for extraglandular
involvement. The armamentarium for
treating systemic manifestations includes
nonsteroidal anti-inflammatory drugs
(NSAIDs), corticosteroids, and immuno-
modulating drugs (eg, hydroxychloro-
quine, methotrexate, azathioprine,
cyclophosphamide, gold compounds).
Primary care providers must do a
risk-benefit analysis for each patient
before prescribing such agents.
Disease manifestations of arthralgias,
myalgias, lymphadenopathy, and fatigue
are generally treated with sahcylates,
NSAIDs, and frequently hydroxychloro-
quine. In fact, the lattermost agent is
one of the most commonly prescribed
medications for patients with Sjogren's
syndrome.^ Although corticosteroids
have no therapeutic role in the glandular
aspects of Sjogren's, they are useful in
patients who have life-threatening com-
plications of the disease,' including vas-
culitis, skin lesions, pneumonitis,
neuropathy, and nephritis. These
patients are usually very ill, and are hos-
pitalized at this point in their illness.
Tapering of the steroids must be done with
caution; drugs such as hydroxychloro-
quine, azathioprine, and methotrexate are
useful during the tapering process.̂  Many
patients with secondary Sjogren's and
underlying connective tissue disease are
treated with low-dose corticosteroids.
Immunomodulating agents are used to
induce remission in patients with acute
inflammatory processes of rheumatic
conditions and internal organ involve-
ment. By controlling the disease process,
these agents may reduce the need for
corticosteroids and allow for their even-
tual discontinuation.'"
Prognosis
As with most chronic progressive ill-
nesses, the rate of progression of
Sjogren's syndrome, either primary or
secondary, is highly variable. In general,
the oral and ophthalmologic manifesta-
tions of the syndrome do not progress.
Some patients experience only mild
xerostomia and xerophthalmia, which
they are able to manage with topical
agents. Others experience cycles of good
health alternating with episodes of seri-
ous illness that are manifested by pro-
gression of the disease. This progression
may include blurred vision, constant eye
discomfort, recurrent candidal infection,
swollen parotid glands, hoarseness, dys-
phagia, and difficulty eating. These
problems, along with debilitating fatigue
and joint pain, contribute to a decreased
quality of life. They may interfere with
simple activities such as watching televi-
sion or reading, as well as with patients'
ability to work or drive. Furthermore,
patient's with primary Sjogren's syndrome
are at increased risk for lymphoprolifera-
tive disorders, including non-Hodgkin's
lymphoma."* Patients with splenomegaly,
bilateral parotid enlargement, and a his-
tory of radiation treatment are at especial-
ly high risk. Secondary Sjogren's can
progress to damage the vital organs of the
body, complicating the illness and the
course of treatment.
Patient Education
Like any chronic illness, Sjogren's syn-
drome can have a profound impact on
patients and family members. All may
beneflt from a close relationship with the
primary care provider, as well as a struc-
tured support organization. Helping
patients to identify their concerns is
paramount in their ability to cope with
the illness. Integrating relaxation tech-
niques and referral to a mental health
professional may be beneficial for select
patients. As direct caregivers, NPs play a
key role in educating patients with
Sjogren's syndrome. As the disease pro-
gresses, they are well suited to counsel
and coach patients through these transi-
tions and to educate patients to maxi-
mize the effectiveness and efficiency of
their treatment regimens. By instructing
patients about proper oral hygiene to
minimize the risk of oral candidiasis and
about proper eye care to prevent dry-
ness, NPs can have a profound impact
on patient adherence and quality of care.
Research
Much research has been performed on
the genetic basis of Sjogren's syndrome
and the nature of the immune compo-
nent. New data are suggestive of viruses
(eg, retroviruses, EBV, HCV) playing a
role in pathogenesis. Numerous clinical
trials are now recruiting patients to
increase clinicians' understanding of
hormonal underpinnings, diagnostic
techniques, pharmacotherapy, and the
long-term effects of the disease.
Conclusion
Sjogren's syndrome is one of the most
common autoimmune diseases, yet it
can go undiagnosed for 8 to 10 years
because of the nature of the signs and
s^Tuptoms. NPs must be able to recog-
nize the clinical features of the syn-
drome, to recommend appropriate
studies to diagnosis it, to begin treat-
ment, and to make appropriate referrals.
Easing symptoms and preventing com-
plications are essential to improving
long-term outcomes in the population
affected by Sjogren's syndrome.
Understanding family dynamics and
encouraging family involvement are
vital components to the care of any
patient with a chronic illness. NPs must
think globally in order to educate
patients, families, collaborating clini-
cians, and researchers to advance the
recognition and treatment of this
autoimmune disease.
Susan DeNisco is an assistant clinical pro-
fessor and coordinator of the Family Nurse
Practitioner Program at Sacred Heart
University in Fairfield, Connecticut, and
she practices at Southwest Community
Health Center in Bridgeport, Connecticut.
Linda Ferro is a nurse practitioner in the
Section of Endocrinology at Norwalk
Hospital, Norwalk, Connecticut.
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